Literature DB >> 17257221

Functional P2X7 receptor polymorphisms (His155Tyr, Arg307Gln, Glu496Ala) in patients with Crohn's disease.

S L Haas1, A Ruether, M V Singer, S Schreiber, U Böcker.   

Abstract

Genetic factors contribute to inflammatory bowel diseases. Recently, the P2X(7) receptor was found to be a key player in caspase-1-mediated processing of the proinflammatory cytokines, interleukin-1beta and interleukin-18. We therefore aimed to determine whether the gain-of-function single nucleotide polymorphism (SNP) His155Tyr and the loss-of-function SNP Arg307Gln and Glu496Ala were associated with susceptibility to Crohn's disease (CD). For association analysis, 681 unrelated CD patients and 736 healthy controls were enrolled. Furthermore, 490 CD trios were included for segregation analysis. Genotyping was performed by the application of the TaqMan(R) MGB biallelic discrimination system. The Arg307Gln polymorphism revealed a borderline significant difference in genotype frequencies between CD patients and controls (P = 0.06) without implying any pathological significance because of low case numbers. Case-control statistics for the variants His155Tyr and Glu496Ala showed no association with CD phenotype (P = 0.19 and 0.99). Subsequent family-based transmission disequilibrium test did not prove an association of the investigated single-nucleotide polymorphisms with CD. In conclusion, the analysed intragenetic variants of the P2X(7) receptor may not be a susceptibility factor for CD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17257221     DOI: 10.1111/j.1365-3083.2006.01876.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  7 in total

Review 1.  Potential for developing purinergic drugs for gastrointestinal diseases.

Authors:  Fernando Ochoa-Cortes; Andromeda Liñán-Rico; Kenneth A Jacobson; Fievos L Christofi
Journal:  Inflamm Bowel Dis       Date:  2014-07       Impact factor: 5.325

2.  Inhibition of P2X7 receptors by Lu AF27139 diminishes colonic hypersensitivity and CNS prostanoid levels in a rat model of visceral pain.

Authors:  Roland G W Staal; Adarsh Gandhi; Hua Zhou; Manuel Cajina; Anne-Marie Jacobsen; Sara Hestehave; Allen Hopper; Suresh Poda; Gamini Chandresana; Stevin H Zorn; Brian Campbell; Marta Segerdahl; Thomas Mӧller; Gordon Munro
Journal:  Purinergic Signal       Date:  2022-08-24       Impact factor: 3.950

3.  The P2X(7) receptor and intracellular pathogens: a continuing struggle.

Authors:  Robson Coutinho-Silva; Gladys Corrêa; Ali Abdul Sater; David M Ojcius
Journal:  Purinergic Signal       Date:  2009-02-12       Impact factor: 3.765

4.  Association of P2X7 receptor genetic polymorphisms and expression with rheumatoid arthritis susceptibility in a sample of the Iranian population: a case-control study.

Authors:  Gholamreza Bahari; Farhad Tabasi; Mohammad Hashemi; Zahra Zakeri; Mohsen Taheri
Journal:  Clin Rheumatol       Date:  2021-02-12       Impact factor: 2.980

5.  Unifying candidate gene and GWAS Approaches in Asthma.

Authors:  Sven Michel; Liming Liang; Martin Depner; Norman Klopp; Andreas Ruether; Ashish Kumar; Michaela Schedel; Christian Vogelberg; Erika von Mutius; Andrea von Berg; Albrecht Bufe; Ernst Rietschel; Andrea Heinzmann; Otto Laub; Burkhard Simma; Thomas Frischer; Jon Genuneit; Ivo G Gut; Stefan Schreiber; Mark Lathrop; Thomas Illig; Michael Kabesch
Journal:  PLoS One       Date:  2010-11-12       Impact factor: 3.240

6.  Lack of a Functioning P2X7 Receptor Leads to Increased Susceptibility to Toxoplasmic Ileitis.

Authors:  Catherine M Miller; Alana M Zakrzewski; Dionne P Robinson; Stephen J Fuller; Robert A Walker; Rowan J Ikin; Shisan J Bao; Michael E Grigg; James S Wiley; Nicholas C Smith
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

Review 7.  Control of Gut Inflammation by Modulation of Purinergic Signaling.

Authors:  Marta Vuerich; Samiran Mukherjee; Simon C Robson; Maria Serena Longhi
Journal:  Front Immunol       Date:  2020-09-25       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.